Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 7Dulaglutide literatureFuture science OA · Case report2026

Severe numbness of the mouth and tongue induced by piperacillin/tazobactam: a rare case report.

Clinicians should be aware that severe adverse reactions to piperacillin/tazobactam can occur, even shortly after administration, and should monitor patients closely.

Read at Future science OAAdd to compare

Where it sits

this study against the rest of the dulaglutide corpus
1
Preclinical
5
Observational · this one
0
Open-label
0
Randomised
1
Reviews

Summary and findings

This case report describes a 58-year-old man who experienced severe oral and tongue numbness, dyspnea, and pruritus approximately 4 minutes after receiving intravenous piperacillin/tazobactam. The adverse reaction was identified as a previously unreported severe adverse drug reaction. No specific dose information was provided in the abstract.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=12026

Abstract

The authors’ words, as Future science OA supplied them

<h4>Background</h4>Severe oral and tongue numbness induced by piperacillin/tazobactam is extremely rare.<h4>Results</h4>A 58-year-old man with bacterial pneumonia developed oral and tongue numbness, dyspnea, and pruritus approximately 4 minutes after intravenous infusion of piperacillin/tazobactam. Based on adverse drug reaction causality assessment, this event was identified as a previously unreported severe adverse drug reaction.<h4>Discussion</h4>This case suggests that during clinical use of piperacillin/tazobactam, clinicians should remain vigilant for rare but severe adverse drug reactions even when skin testing is negative, and strengthen medication monitoring to ensure medication safety.

Background

This paper addresses the rare occurrence of severe oral and tongue numbness as an adverse reaction to piperacillin/tazobactam. While adverse drug reactions are known to occur with various medications, this specific reaction appears to be previously unreported. Understanding such rare reactions is critical for improving medication safety and monitoring practices in clinical settings.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

The findings highlight the importance of vigilance in monitoring for rare adverse drug reactions, even when prior testing does not indicate sensitivity. However, due to the nature of a single case report, the findings may not be broadly applicable or clinically significant across larger populations.

Key findings

  • Severe oral and tongue numbness occurred 4 minutes after intravenous infusion of piperacillin/tazobactam.
  • The patient was a 58-year-old man with bacterial pneumonia.
  • The adverse reaction was classified as a previously unreported severe adverse drug reaction.

Limitations

  • Single case report limits generalizability.
  • No specific dose or duration of treatment reported.
  • Lack of larger sample size to support findings.
  • No follow-up data provided.

Elsewhere in the Dulaglutide corpus

DA comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.The lancet. Diabetes & endocrinology · 2026ASerial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.American heart journal · 2026 · n=4292 · Adjusted HR per 1 integer unit of baseline NT-proBNP for MACE was 1.63, P < .001.HumanBVirtual shared medical appointments for obesity and GLP-1 medications: A scalable method for optimizing care delivery.Obesity pillars · 2026 · n=54 · Weight decreased from 227 lb (53 lb) to 211 lb (46 lb), n=17.HumanBClinical perspectives on pediatric weight-management programs: A nationwide look at models of care.Obesity pillars · 2026 · n=38 · Not reported in abstract.HumanBCalculating cost per event avoided using a composite number needed to treat.Journal of medical economics · 2026 · $1,884,013 for CPEA of dulaglutide MACE-3HumanACardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2026 · n=21717 · RR for all-cause mortality was 0.83; 95% CI, 0.76-0.90.Human